Effect of thalidomide on gastrointestinal toxic effects of irinotecan

Irinotecan is the only accepted second-line treatment for colorectal cancer in the USA. Doses are, however, frequently limited by associated late-onset diarrhoea. Thalidomide has antiangiogenic and immunomodulatory properties and is being investigated as an antineoplastic. We did a pilot study of co...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 2000-08, Vol.356 (9229), p.566-567
Hauptverfasser:	Govindarajan, Rangaswamy, Heaton, Keith M, Broadwater, J Ralph, Zeitlin, Andrew, Lang, Nicholas P, Hauer-Jensen, Martin
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic agents Antineoplastic Agents, Phytogenic - administration & dosage Antineoplastic Agents, Phytogenic - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Camptothecin - administration & dosage Camptothecin - adverse effects Camptothecin - analogs & derivatives Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Diarrhea - chemically induced Diarrhea - prevention & control Digestive system Digestive System - drug effects Gastroenterology. Liver. Pancreas. Abdomen Humans Irinotecan Medical research Medical sciences Pharmacology. Drug treatments Pilot Projects Prescription drugs Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Thalidomide - administration & dosage Thalidomide - therapeutic use Toxicity Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!